Xenetic Biosciences, Inc. (XBIO)
| Market Cap | 24.57M |
| Revenue (ttm) | 302,676 |
| Net Income (ttm) | -10.86M |
| Shares Out | 6.30M |
| EPS (ttm) | -1.76 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 19 |
| Last Price | $2.76 |
| Previous Close | $2.72 |
| Change ($) | 0.04 |
| Change (%) | 1.47% |
| Day's Open | 2.73 |
| Day's Range | 2.66 - 2.85 |
| Day's Volume | 549,289 |
| 52-Week Range | 0.49 - 3.17 |
FRAMINGHAM, MA / ACCESSWIRE / January 14, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized C...
FRAMINGHAM, MA / ACCESSWIRE / January 5, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CA...
Shares of Xenetic Biosciences Inc (NASDAQ: XBIO), a drug delivery platform company, were ripping higher Wednesday on markedly above-average volume. What Happened: The Framingham, Massachusetts...
Shares of Xenetic Biosciences Inc. skyrocketed on massive volume toward a 17-month high in morning trading Wednesday, after the Massachusetts-based biopharmaceutical company said its partner P...
The stock price of Xenetic Biosciences, Inc. (NASDAQ:XBIO) are trading at over 300% as it went from $1.08 in the previous close to $4.88 as of 11:17 AM ET. This is why it happened.
Xenetic Biosciences (XBIO) news for Wednesday includes positive news from a Phase 3 clinical trial boosting XBIO stock higher. The post Xenetic Biosciences News: Why XBIO Stock Is Going Ballis...
Nano-cap biotech Xenetic Biosciences Inc.'s stock was rallying Friday following an announcement concerning pricing for its previously announced offering of common stock and accompanying warrants.
About XBIO
Xenetic Biosciences, a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and novel oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. The company is also leveraging PolyXen, its proprietary... [Read more...]
| Industry Biotechnology | |
| CEO Jeffrey F. Eisenberg | Employees 4 |
| Stock Exchange NASDAQ | Ticker Symbol XBIO |
Analyst Forecasts
According to 2 analysts, the average rating for XBIO stock is "Buy." The 12-month stock price forecast is 3.75, which is an increase of 35.87% from the latest price.